LifeMD (LFMD) reported a third-quarter loss of $0.11 per share, $0.03 better than the -$0.14 consensus for a 21.4% earnings surprise. That beat is the least important number in the report. Revenue of $44.63 million missed the $48.79 million consensus by 8.5% and fell short of management's own $48-51 million guide. The company also cut its full-year outlook for the second straight quarter and guided fourth-quarter revenue to $46-49 million, down from the $60-64 million it projected three months ago. The central tension is that LifeMD has shown it can cut costs, but it has not yet shown it can grow while doing so.

The year-over-year comparisons depend on the basis used. On Earnings Whispers' normalized basis, revenue fell 25.8% and earnings declined 10.0%. That is consistent with total loss per share widening from $0.10 to $0.11 once last year's WorkSimpli contribution is included. On the company's continuing-operations basis, which excludes the divested WorkSimpli unit, revenue fell about 7% and the per-share loss narrowed slightly from $0.12. Either way, the top line is shrinking. Revenue has slid from $50.2 million in Q1 to $47.3 million in Q2 and $44.6 million now.

The quality of the beat deserves scrutiny. The improvement came from spending less, not selling more. Adjusted EBITDA improved to a loss of roughly $0.4 million from losses of $3.5 million in Q2 and $4.5 million in Q1. That landed inside guidance but missed management's Q2 pledge of third-quarter EBITDA profitability. Selling and marketing expense was cut 34% sequentially to $18.5 million. Cost per acquisition is down 40% from its June peak, and roughly 85% of new patients now choose multi-month plans, compared with about 25% before the pricing change.

The patient base is not holding up as well. Active subscribers of about 350,000 are up 13% year over year but have declined each quarter from 365,000 in Q1 and 356,000 in Q2. Weight-management patients fell to about 104,000 from 108,000. Management also acknowledged that early-2026 patient cohorts underperformed.

The call marked a clear shift in tone. Earlier this year management was reaffirming targets. This quarter it effectively conceded the reset. The roughly $250 million exit run-rate promised on every prior call is now about $200 million, and the annualized EBITDA exit targets have been abandoned. Full-year EBITDA guidance of -$12.6 million to -$10.6 million compares with -$6 million to breakeven last quarter and +$12-17 million originally. An immaterial revenue-recognition error tied to third-party pharmacy arrangements also delayed the 10-Q, which does little to rebuild credibility.

The forward narrative now rests on the pharmacy:

• **Branded GLP-1 dispensing.** Arrangements with Eli Lilly and Novo Nordisk let LifeMD's pharmacy dispense drugs including Wegovy, Ozempic, Zepbound and Foundayo.
• **Pharmacy momentum.** Orders rose 17% sequentially, and October volume grew 27% after Novo fulfillment began.
• **AT&T distribution.** The partnership is live in 11 states and is slated for national rollout in January 2027.
• **Other initiatives.** Management outlined an enterprise self-pay offering, talks with more than ten virtual-health platforms on pharmacy services, peptide launches, and a preliminary ambition for about 30% revenue growth in 2027 on flat fixed overhead.

That growth ambition sits outside formal guidance, and partnership timing is partly beyond the company's control.

The pharmacy pivot also changes the economics. Branded drugs are booked on a gross revenue basis, so gross margin fell to 82% from 89% in Q2. Management guides it to the high-50s or low-60s by the end of 2027. The business also needs more working capital:

• Inventory rose to $10.3 million from $2.8 million at year-end.
• Receivables climbed to $13.2 million.
• Accounts payable swelled to $37.7 million.
• Cash fell to $21.9 million, and stockholders' equity turned slightly negative.

The $12.5 million Avenue Capital term loan adds flexibility, but bears have legitimate ammunition on the balance sheet.

The market had largely priced in disappointment before the release. Shares closed at $1.78 heading into the report, down 44.7% from the $3.22 open after the August release. They sat about 51% below the $3.60 200-day moving average and just 6.6% above the 52-week low of $1.67 set the day before earnings. Price, momentum and AVWAP trend readings remain negative. Investor sentiment improved from -0.45 to -0.21, a meaningful move, but it is still negative and suggests expectations had moderated rather than turned constructive.

The bottom line is that LifeMD delivered an earnings beat built on cost discipline while its revenue base, subscriber count and guidance all moved the wrong way. The Lilly, Novo and AT&T relationships give the company a credible path to reigniting growth. For now, though, the investment case depends on 2027 execution that management has not yet put into guidance, funded by a balance sheet that has tightened noticeably.